37 results about "Chronic rhinosinusitis" patented technology

Disclosed are methods and apparatus for safe, simple and effective broad-spectrum treatments of chronic rhinosinusitis and other common and less common infections of the sino-nasal tract which may implicate not only a wide range of bacterial species but also fungi and viruses. Electromagnetic radiative energy including visible, and optionally, thermal RF, microwave or other longer wavelengths, is applied to target internal surfaces of the sino-nasal tract to destroy or incapacitate superficial microorganisms without the use of antibiotics. The treatment can be controlled to permit regrowth of healthy microflora. A handheld energy applicator has a light output head receivable into, or engageable with, the treatment subject's nostril which may be provided with extensions to reach the sinuses. Useful embodiments of the invention include pretreatment of target sino-nasal surfaces with a photosensitizing agent such as an oxidizing agent or a complementary stain. For example methylene blue can be used with orange or red light. The combination treatment of photosensitizer and application of visual wavelength energy provides a flexible treatment regimen which enables low concentrations of stains to be employed, minimizing aesthetic problems.

Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.

Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.

In some aspects, the present invention provides methods treating a subject in need of treatment for chronic rhinosinusitis or nasal polyposis, the methods comprising administering a complement inhibitor such as a compstatin analog to the subject. In some embodiments, the complement inhibitor is administered intranasally, e.g., in a nasal spray.

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

Method for treating chronic rhinosinusitis in a human patient. In the method a photosensitizing agent such as indocyanine green can be applied to color a nasal or sinal treatment site harboring infectious microorganisms. The photosensitizing agent can have an energy absorption peak in a near infrared wavelength region of the electromagnetic spectrum. The method can also include applying light energy from a laser source at a near infrared wavelength or wavelengths to the colored treatment site, for a duration sufficient to control the microorganisms. Apparatus for performing the method is also disclosed.

The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

The invention discloses a Chinese medicinal preparation for treating chronic rhinosinusitis, which is characterized by being prepared from the following raw Chinese medicinal herbs in percentage by weight, 6.7-10.2 % of magnolia flower, 6.7-10.2 % of dark plum, 3.4-6.8 % of dahurian angelica root, 6.7-10.2 % of siberian cocklour fruit, 15.3-18.6 % of astragalus root, 6.7-10.2 % of chrysanthemum, 6.7-10.2 % of Chinese thorowax root, 3.4-6.8 % of cicada slough, 3.4-6.8 % of honey-fried Chinese ephedra, 6.8-10.2 % of honey-fried licorice root, 6.8-10.2 % of paniculate swallowwort root and 6.8-10.2 % of India madder root. The Chinese medicinal preparation for treating chronic rhinosinusitis has the advantages of reasonable formulation, convenience for taking, no toxic or side effects, has the functions of increasing immunity, shortening the curing time for chronic rhinosinusitis and improving a therapeutic effect, and can be widely used for treating the chronic rhinosinusitis.

The invention provides methods and compositions for the prevention and treatment of Siglec-8 associated diseases such as chronic rhino sinusitis with concomitant asthma and aspirin-exacerbated respiratory disease. In particular, the invention provides methods for the prevention and treatment of Siglec-8 associated diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of Siglec-8 associated diseases such as chronic rhinosinusitis with concomitant asthma and aspirin-exacerbated respiratory disease.

The invention discloses a Chinese medicinal preparation for treating chronic rhinosinusitis and a preparation method thereof. The preparation comprises the following raw materials in part by weight: 1 to 2 parts of heartleaf houttuynia herb, 1 to 2 parts of baical skullcap root and 1 to 2 parts of chilly. The preparation method comprises the following steps of: mixing the Chinese medicinal raw materials in proportion; extracting fat-soluble components in the Chinese medicinal materials; and then preparing the Chinese medicinal materials into required Chinese medicinal formulations by a conventional method. Convention is broken through; a spicy medicament, namely the chilly is creatively introduced and has scientific compatibility with other Chinese medicinal medicaments; and the preparation has good curative effect and small side effects.

Provided is a composition for preventing, ameliorating, or treating inflammatory diseases, the composition including, as active ingredients, lactic acid bacteria-derived extracellular vesicles isolated from culture fluid of lactic acid bacteria; and a method for diagnosing atopic dermatitis. The composition including the lactic acid bacteria-derived extracellular vesicles as active ingredients is expected to be usefully used in development of drugs, cosmetics, or health functional food for preventing, ameliorating, or treating inflammatory diseases such as atopic dermatitis, chronic rhinitis, chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease, sepsis, etc. Also, the composition will be usefully used for diagnosis of atopic dermatitis by measuring the distribution of lactic acid bacteria-derived extracellular vesicles in a urine or blood sample.

The invention discloses a Chinese medicinal preparation for treating chronic rhinosinusitis, which is characterized by being prepared from the following raw Chinese medicinal herbs in percentage by weight, 6.7-10.2 % of magnolia flower, 6.7-10.2 % of dark plum, 3.4-6.8 % of dahurian angelica root, 6.7-10.2 % of siberian cocklour fruit, 15.3-18.6 % of astragalus root, 6.7-10.2 % of chrysanthemum, 6.7-10.2 % of Chinese thorowax root, 3.4-6.8 % of cicada slough, 3.4-6.8 % of honey-fried Chinese ephedra, 6.8-10.2 % of honey-fried licorice root, 6.8-10.2 % of paniculate swallowwort root and 6.8-10.2 % of India madder root. The Chinese medicinal preparation for treating chronic rhinosinusitis has the advantages of reasonable formulation, convenience for taking, no toxic or side effects, has thefunctions of increasing immunity, shortening the curing time for chronic rhinosinusitis and improving a therapeutic effect, and can be widely used for treating the chronic rhinosinusitis.

The invention relates to a medicament, in particular to a medicament for treating chronic rhinosinusitis, which is prepared from many traditional Chinese medicines serving as raw materials. The invention mainly solves the problems of serious side effects, susceptibility to causing medicament resistance, undesirable treatment effect, incapability of suppressing relapse and the like of the conventional medicaments for treating chronic rhinosinusitis. The medicament of the invention is prepared by proportioning Chinese ligusticum rhizome, biond magnolia flower, thunberg fritillary bulb, pseudo-ginseng, dendrobe, coasiaI gIehnia root, bunge cherry seed, scrophularia ningpoensis, dwarf lilyturf tuber, fragrant solomonseal rhizome, the root of Chinese thorowax, indigowoad leaf, scaphium scaphigerum, Scutellaria baicalensis, rough gentian, indigo naturalis, liquoric root, talcum powder, asiatic moonseed rhizome, blackberry lily, Platycodon grandiflorum, mint, hawthorn, bombyx batryticatus, great burdock achene, mongolian snakegourd root, Chinese date and ginger. In the invention, the traditional Chinese medicines are used for treatment and conditioning, so the side effects are fewer, medicament resistance is not generated in a taking process, both the symptoms and root causes are address, the treatment effect is remarkable, the cure rate is high, surgery is not needed, and extra injury to the patient is avoided.

The invention provides a drug-loading nanofiber membrane for preventing nasal infection and adhesion and a preparation method thereof; the drug-loading nanofiber membrane comprises poly-L-lactic acid,polyvinylpyrrolidone and clarithromycin; the drug-loading nanofiber membrane has a fiber diameter less than 10 micrometers. According to the invention, after being loaded with clarithromycin, the poly-L-lactic acid and PVP composite fiber membrane can be implanted and adhered to the nasal cavity and paranasal sinuses to continuously release the clarithromycin, can degrade by itself and can play antibacterial, anti-inflammatory and anti-adhesion roles after chronic rhinosinusitis and nasosinusitis surgeries, thereby preventing postoperative repeated infection, adhesion and other complications.The drug-loading nanofiber membrane provided by the invention can be used for preventing infection and adhesion of nasal cavities and sinuses, and has the advantages of convenience in use, avoidanceof repeated drug administration, avoidance of adverse reactions of systemic drug administration and the like.

Method for treating chronic rhinosinusitis in a human patient. In the method a photosensitizing agent such as indocyanine green can be applied to color a nasal or sinal treatment site harboring infectious microorganisms. The photosensitizing agent can have an energy absorption peak in a near infrared wavelength region of the electromagnetic spectrum. The method can also include applying light energy from a laser source at a near infrared red wavelength or wavelengths to the colored treatment site, for a duration sufficient to control the microorganisms. Apparatus for performing the method is also disclosed.

The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.

Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e.g., the nasal mucosa, for the treatment of respiratory tract and / or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such as branched, sulfated polysaccharides having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups or extracts from brown algae. Also disclosed are methods and pharmaceutical compositions for treating respiratory tract and / or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis.

Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e.g., the nasal mucosa, for the treatment of respiratory tract and / or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such as branched, sulfated polysaccharides having an average molecular weight greater than 4 kDa and comprising L-fucose and sulfate ester groups or extracts from brown algae. Also disclosed are methods and pharmaceutical compositions for treating respiratory tract and / or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis.

The present invention provides a method for identifying bacterial induced rhinosinusitis. The method comprises obtaining a nasal or paranasal mucus sample and detecting the presence of neutrophil degranulation in the mucus sample. Degranulation of neutrophils can be determined by morphological analysis of the cells in the mucus or by detection of released (i.e., “free”) granule content markers such as neutrophil elastase or myeloperoxidase. Based on an accurate determination of the cause of sinusitis as described herein, an appropriate treatment can be instituted.

The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.

The invention discloses a traditional Chinese medicine drug for treating rhinitis and a processing method thereof. The formula comprises 5-10 parts of biond magnolia flowers, 5-10 parts of fineleaf schizonepeta herb, 5-10 parts of siberian cocklebur fruits, 3-10 parts of dahurian angelica roots, 3-10 parts of Chinese gentian, 3-10 parts of forsythia fruits, 5-10 parts of honeysuckles, 1-5 parts ofSichuan lovage rhizomes, 3-10 parts of winkled gianthyssop herb, 1-5 parts of divaricate saposhnikovia roots, 3-10 parts of incised notopterygium rhizomes, 1-3 parts of manchurian wildginger, 2-3 parts of Yunnan poria cocos, 5-10 parts of scorched largehead atractylodes rhizomes, 3-10 parts of mint, 1-5 parts of Chinese honeylocust fruits and 1-6 parts of an excipient. The processing method comprises the following steps: step 1, selection of raw materials; step 2, pretreatment of the raw materials; step 3, grinding of the raw materials; step 4, preparation of watered pills; and step 5, inspecting and packaging. According to the traditional Chinese medicine drug for treating rhinitis and the processing method thereof, the drug can effectively treat common cold complications such as variousrhinosinusitis, chronic rhinosinusitis and frontal sinusitis, and has the advantages of mild drug effect, obvious response, high cure rate and low recurrence rate.

The invention provides a method of treating chronic rhinosinusitis such as allergic fungal sinusitis comprising daily oral administration of a composition from more than 500 mg to about 800 mg, preferably about 625 mg or 725 mg terbinafine base equivalent as hydrochloride, or a molar equivalent in other acid addition salt or free base form, for a duration effective to reduce the symptoms of, or eliminate chronic rhinosinusitis; it further concerns the use of terbinafine in the manufacture of a corresponding medicament, and packs containing a plurality of corresponding compositions and medicaments.

The invention relates to the field of molecular biological detection, in particular to application of Cystatin SN in forecast of sensitivity of a chronic rhinosinusitis with polyposis patient on glucocorticoid. A sample collection method of a forecast method is safe and non-invasive, is good in tolerance, simple and rapid in detection method and favorable in forecast performance and has favorable clinical application prospect.

A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.

The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.

The invention discloses a traditional Chinese medicine nasal drop for treating chronic nasosinusitis and a preparation method thereof. The traditional Chinese medicine nasal drop comprises: biond magnolia flower-bud, dahurian angelica roots, herba houttuyniae, loofah sponge, spina gleditsiae, centipeda minima, rhizoma chuanxiong, herba ephedrae, radix scutellariae, menthol and frankincense. The preparation method comprises the following steps: soaking the biond magnolia flower-bud, the dahurian angelica roots, the herba houttuyniae, the loofah sponge, the spina gleditsiae, the centipeda minima, the rhizoma chuanxiong, the herba ephedrae and the radix scutellariae in sesame oil, performing heating with slow fire, fishing out the medicinal materials when the medicinal materials are fried toyellowish-brown, performing standing and filtering, co-grinding the menthol and the frankincense, adding liquid paraffin, performing uniform stirring and filtering, and uniformly mixing the filtered material with sesame oil. The nasal drop is prepared from pure traditional Chinese medicines, has scientific and reasonable compatibility of components, and has the effects of dispelling wind and clearing heat, inducing diuresis to alleviate edema, inducing resuscitation with fragrance and promoting blood circulation to arrest pain; and the preparation method is simple, small in side effect, low inprice and remarkable in curative effect, and has a clinical cure rate up tp 89%.

The invention discloses a traditional Chinese medicine preparation for treating chronic rhinosinusitis and a preparation method thereof. The preparation comprises the following parts by weight: 1-2 parts of Houttuynia cordata, 1-2 parts of Scutellaria baicalensis, and 1-2 parts of pepper. The raw materials of traditional Chinese medicine are mixed in proportion, the fat-soluble components in the medicinal material are extracted, and then the required medicinal dosage form is prepared according to a conventional method. In the traditional Chinese medicine preparation for treating chronic rhinosinusitis of the present invention, the spicy medicine capsicum is creatively introduced, which is scientifically compatible with other traditional Chinese medicines, and has good therapeutic effect and less side effects.

The invention relates to a medicament, in particular to a medicament for treating chronic rhinosinusitis, which is prepared from many traditional Chinese medicines serving as raw materials. The invention mainly solves the problems of serious side effects, susceptibility to causing medicament resistance, undesirable treatment effect, incapability of suppressing relapse and the like of the conventional medicaments for treating chronic rhinosinusitis. The medicament of the invention is prepared by proportioning Chinese ligusticum rhizome, biond magnolia flower, thunberg fritillary bulb, pseudo-ginseng, dendrobe, coasiaI gIehnia root, bunge cherry seed, scrophularia ningpoensis, dwarf lilyturf tuber, fragrant solomonseal rhizome, the root of Chinese thorowax, indigowoad leaf, scaphium scaphigerum, Scutellaria baicalensis, rough gentian, indigo naturalis, liquoric root, talcum powder, asiatic moonseed rhizome, blackberry lily, Platycodon grandiflorum, mint, hawthorn, bombyx batryticatus, great burdock achene, mongolian snakegourd root, Chinese date and ginger. In the invention, the traditional Chinese medicines are used for treatment and conditioning, so the side effects are fewer, medicament resistance is not generated in a taking process, both the symptoms and root causes are address, the treatment effect is remarkable, the cure rate is high, surgery is not needed, and extra injury to the patient is avoided.